Bloom Burton analyst David Martin PhD has maintained their bullish stance on KHTRF stock, giving a Buy rating on March 21.
David Martin PhD has given his Buy rating due to a combination of factors that indicate strong financial performance and promising future prospects for Knight Therapeutics. The company reported fourth-quarter results for 2024 that exceeded expectations, primarily driven by a significant contract renewal with the Brazilian Ministry of Health, which was not anticipated in prior forecasts. This contract contributed to a notable increase in revenue projections for 2025.
Additionally, Knight Therapeutics demonstrated impressive year-over-year revenue growth, particularly in its infectious disease portfolio. The growth was substantial even when adjusted for hyperinflation, showcasing the company’s robust performance in a challenging economic environment. These factors collectively support the Buy rating, as they suggest Knight Therapeutics is well-positioned for continued success and expansion in its market segments.
In another report released on March 21, Stifel Nicolaus also maintained a Buy rating on the stock with a C$6.25 price target.
Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KHTRF in relation to earlier this year.